ToxicoGenomica Blog

Free Perrin Webinar on April 10 2025: Updates on BAP1 and BRCA Genes as Causes of Mesothliomas and Other Cancers – Don’t Miss the Latest Developments

| March 21, 2025

Join us for this complimentary CLE webinar on April 10, 2025 from 2:00-3:40 PM ET CLICK HERE TO REGISTER FOR WEBINAR On April 10 at 2pm ET, please join us for Toxicogenomica’s free webinar focused on inherited mutations that cause mesotheliomas and other cancers, independent of asbestos or other toxicants. This webinar will cover important 2024 […]

Learn More

ToxicoGenomica at Perrin Conference 2023: Not All Tumor Suppressor Genes are Equivalent

| October 27, 2023

ToxicoGenomica recently presented at the National Asbestos Litigation Conference (September 12-13, 2023) hosted by Perrin Conferences and the slides are now available for download. Len van Zyl, Ph.D, and CEO of ArrayXpress participated in an engaging panel moderated by Douglas Sinars, Esq. and titled Medical & Scientific Literature Update on Asbestos & Mesothelioma. The panel […]

Learn More
ToxicoGenomica

2023 Brings Multiple Waves Of Additional Studies Regarding Mesotheliomas And Other Cancers Caused Solely By Genomic Factors

| September 5, 2023

ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The webinar focused on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It also covered predictive software and other tools for understanding the impact of germline mutations on disease development and progression. The speakers […]

Learn More
DNA

Perrin Conferences Presents: 2023 Brings Multiple Waves of Additional Studies Regarding Mesotheliomas and Other Cancers Caused Solely by Genomic Factors

| June 1, 2023

Join us for this complimentary CLE webinar on Tuesday, July 18, 2023 from 2:00-3:30 pm ET. This webinar will focus on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It will also cover predictive software and other tools for understanding the impact of germline mutations on disease development and progression. There […]

Learn More
DNA

Perrin Conferences Presents: Cutting-Edge Issues in Asbestos Litigation

| March 2, 2023

Kirk Hartley of ToxicoGenomica will cover the topic of the continually increasing value of genomic analysis to evaluate mesothelioma causation at the upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation. As part of a panel on genetics and science, Kirk will discuss important new papers with data showing the increasing findings of genomic drivers of mesotheliomas. One portion […]

Learn More

Key Developments in the Use of Genomics in Mesothelioma Cases: Causal Role of BAP1 Null (Loss of Function) Mutations in Mesothelioma and Key Legal Findings

| December 19, 2022

ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The title of the session was Key Developments: Genomics in Mesothelioma Cases. The webinar focused on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics […]

Learn More

Perrin Conferences Present: Key Developments – Genomics in Mesothelioma

| November 21, 2022

Complimentary CLE Webinar Thursday, December 1st, 2022 1:30-2:45 ET Click Here For More Information and to Register This webinar will focus on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics to understanding the causes of cancer. MEET THE SPEAKERS • Kirk […]

Learn More

How hidden protective mutations can change the course of a toxic tort case

| June 8, 2022

Identifying protective mutations through comprehensive genetic screening gives litigators more leverage to argue disease causation in court. Protective mutations are certain altered points in an individual’s DNA that can give them robust resistance to developing disease even if exposed to a known causative agent. Accordingly, if genetic testing shows that a particular person harbors resistance […]

Learn More

Findings from new ALS genetics study could change courtroom arguments

| May 25, 2022

Stakeholders involved in toxic tort litigation involving Amyotrophic Lateral Sclerosis (ALS) will want to understand the implications of a recent study that identified previously unknown genetic factors involved in the development of this disease. The authors explained that the results are notable for multiple reasons, including “reveal[ing] genetic variants that protect against ALS by reducing […]

Learn More

Newly discovered features of glioblastoma could change the course of legal defenses

| May 11, 2022

Legal defenses in toxic tort cases regarding mesothelioma or lymphoma are increasingly dependent on genetic evidence demonstrating genetic predisposition – i.e., demonstrating that the cancer was caused by genetic defects that the plaintiff inherited. In the case of other cancers, however, litigators may face a lack of data supporting legal arguments of predisposition. For litigators […]

Learn More